| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84196 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
161 |
wyh |
2024-12-19 |
| 84197 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
178 |
zyl |
2024-12-19 |
| 84198 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
210 |
WYQ |
2024-12-19 |
| 84199 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
184 |
kx |
2024-12-19 |
| 84200 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
170 |
h |
2024-12-19 |
| 84201 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
161 |
WYQ |
2024-12-19 |
| 84202 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
141 |
wyh |
2024-12-19 |
| 84203 |
cas:330970-70-2 Alloc-Val-Ala-OH |
186 |
zyl |
2024-12-19 |
| 84204 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
170 |
h |
2024-12-19 |
| 84205 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
158 |
WYQ |
2024-12-19 |
| 84206 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
177 |
kx |
2024-12-19 |
| 84207 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
147 |
WYQ |
2024-12-19 |
| 84208 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
262 |
kx |
2024-12-19 |
| 84209 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
193 |
WYQ |
2024-12-19 |
| 84210 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
179 |
h |
2024-12-19 |
| 84211 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
210 |
zyl |
2024-12-19 |
| 84212 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
167 |
WYQ |
2024-12-19 |
| 84213 |
Boc-Val-Cit CAS:870487-08-4 |
244 |
zyl |
2024-12-19 |
| 84214 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
182 |
h |
2024-12-19 |
| 84215 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
150 |
kx |
2024-12-19 |
| 84216 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
153 |
h |
2024-12-19 |
| 84217 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
139 |
kx |
2024-12-19 |
| 84218 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
233 |
zyl |
2024-12-19 |
| 84219 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
114 |
kx |
2024-12-19 |
| 84220 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
129 |
zyl |
2024-12-19 |
| 84221 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
141 |
kx |
2024-12-19 |
| 84222 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
103 |
kx |
2024-12-19 |
| 84223 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
120 |
h |
2024-12-19 |
| 84224 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
146 |
h |
2024-12-19 |
| 84225 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
159 |
kx |
2024-12-19 |
| 84226 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
182 |
h |
2024-12-19 |
| 84227 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
132 |
h |
2024-12-19 |
| 84228 |
cas:2762518-86-3，NHS Ester-PEG4-Val-Cit-PAB-MMAE， ADC试剂 |
178 |
kx |
2024-12-19 |
| 84229 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
180 |
h |
2024-12-19 |
| 84230 |
cas:2353409-45-5，BCN-PEG3-Val-Cit-PFP Ester， ADC试剂 |
148 |
kx |
2024-12-19 |
| 84231 |
cas:2112738-13-1，Mal-amido-PEG2-Val-Cit-PAB-PNP， ADC试剂 |
119 |
kx |
2024-12-19 |
| 84232 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH， ADC试剂 |
175 |
kx |
2024-12-19 |
| 84233 |
cas:2055024-62-7，NH2-PEG3-Val-Cit-PAB-OH， ADC试剂 |
216 |
kx |
2024-12-19 |
| 84234 |
Fmoc-PEG3-Val-Cit，N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
173 |
kx |
2024-12-19 |
| 84235 |
DOTA-anti-VLA-4 |
152 |
h |
2024-12-19 |
| 84236 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
142 |
h |
2024-12-19 |
| 84237 |
CAS: 2748039-76-9， Alkyne-Val-Cit-PAB-FAM，炔-Val-Cit-PAB-FAM |
141 |
WYQ |
2024-12-19 |
| 84238 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
194 |
zyl |
2024-12-19 |
| 84239 |
Amino-PEG2-VG-N-Bis(PEG1-azide)，氨基-二聚乙二醇-VG-N-双（一聚乙二醇-叠氮） |
156 |
WYQ |
2024-12-19 |
| 84240 |
Azido-PEG8-Val-Cit-PAB-PNP，C34H47N9O12 |
141 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询